Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Coronavirus channel feed
As Covid research heats up, J&J retires a BARDA-funded flu antiviral they worked on for 7 years
5 years ago
R&D
Covid-19 roundup: Albert Bourla says Pfizer PhIII is at 23,000 patients, submission coming end of October
5 years ago
R&D
Coming up behind the mRNA leaders, Sanofi, GSK pivot into PhI/II trial for their traditional tech approach to a Covid-19 vaccine. This race isn't over yet
5 years ago
R&D
Covid-19 roundup: KHN: Fauci says Covid vaccine trials could end early, if...; HHS plans $250M campaign to 'defeat despair and inspire hope'
5 years ago
That 'historic breakthrough' hyped by Trump and Hahn? The NIH isn't impressed
5 years ago
As fears of a politically-motivated vaccine EUA grow, Eric Topol delivers an ultimatum to commissioner Hahn: Stand up or resign
5 years ago
Covid-19 roundup: AstraZeneca launches 3rd US PhIII vaccine study with a vow to avoid 'cutting corners'
5 years ago
Sanofi, Regeneron hit final nail on the IL-6 repurposing coffin as Kevzara fails PhIII
5 years ago
R&D
GSK, Vir barrel into a fast PhII/III for their lead Covid-19 antibody, chasing a moving target with quick OK in sight
5 years ago
R&D
Covid-19 roundup: Most Americans worry politics is put before science amid vaccine rush; Daiichi Sankyo furthers mRNA shot R&D
5 years ago
Paul Hudson is more confident in Sanofi's ability to produce a Covid-19 vaccine — report
5 years ago
FDA commissioner Hahn ousts agency’s new chief spokesperson as plasma controversy continues to smolder
5 years ago
People
Covid-19 roundup: J&J launching new PhII vaccine trials in Europe; Abbott scores $760M testing kit order from HHS
5 years ago
Trump promises a safe, effective vaccine for Covid-19 before year’s end — 'or maybe even sooner!' So where does that leave the FDA?
5 years ago
Bioregnum
Opinion
Covid-19 roundup: BeiGene snags rights to potential antibody treatment; Beefing up manufacturing ops, Regeneron adds 400 jobs at Irish facility
5 years ago
FDA commish Hahn spotlights Oct 22 vaccine advisory meeting as the next big flashpoint in the Covid-19 campaign
5 years ago
Bioregnum
Opinion
Moderna takes one more step along the high-wire act of Covid-19 vaccine work, offering markers of success for the most vulnerable age group
5 years ago
R&D
Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight
5 years ago
Financing
Covid-19 roundup: European vaccines lobby pushing for liability protection; VBI vaccines to prep human trials
5 years ago
Covid-19 roundup: Biogen conference is tied to tens of thousands of Covid-19 cases; FDA chief Stephen Hahn walks back plasma comments
5 years ago
Exclusive: We asked for biopharma's opinion about the plasma EUA. The industry offered a double-barreled response
5 years ago
FDA+
Covid-19 roundup: Novavax begins PhII trial in US and Australia; AstraZeneca signs US manufacturing deal with Catalent
5 years ago
Trump heralds a 'historic breakthrough' in the R&D fight against Covid-19 — now comes the instant backlash as the FDA provides a controversial assist
5 years ago
FDA+
The leaders in the race to develop a Covid-19 vaccine say they could have pivotal data in October — but Trump claims FDA is slowing recruitment
5 years ago
Bioregnum
Opinion
First page
Previous page
44
45
46
47
48
49
50
Next page
Last page